A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker
- 09 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 09 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 01 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 31 Dec 2020.